FDA Drug Approvals for Cancer in 2014

Slideshow

This slide show highlights the 2014 FDA approvals of cancer treatments, which included therapies for melanoma and lung, gastric, ovarian, and cervical cancers, as well as various hematologic malignancies.

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on lung cancer
A panel of 4 experts on multiple myeloma
A panel of 4 experts on lung cancer
Video 8 - "Closing Thoughts on the Future of NSCLC"
Video 7 - "Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC "
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Related Content
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?

51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?

May 18th 2024
Article
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

May 13th 2024
Podcast

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

May 17th 2024
Article
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

May 17th 2024
Article

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care

AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care

May 17th 2024
Article

Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.